Managing Partner of Prevail Venture Capital Fund I, with prior operating experience inside Salient Surgical and a career in healthcare and medical-device development.
At a Glance
- Early member of the Salient Surgical team, which was acquired by Medtronic in 2011 for $645 million.
- Subsequently led development at a private-equity-backed high-acuity surgery center business that transacted in 2022.
- Co-founder of NextStage Clinical Research, a company focused on bringing clinical trials to community physicians.
- Leads Fund I and serves on the boards of MedTech portfolio companies for which Prevail acts as lead investor.
Background
Tim Bledsoe began his career in healthcare and medical-device development and was an early member of the Salient Surgical team. Salient was acquired by Medtronic in 2011 for $645 million, a transaction that remains one of the larger MedTech outcomes in the collective experience of the Prevail team.
Following the Salient transaction, Tim led development at a private-equity-backed high-acuity surgery center business through its 2022 transaction. He is also a co-founder of NextStage Clinical Research, a company focused on extending clinical-trial access to community-physician networks, addressing a structural gap in how new therapeutics are evaluated outside of major academic medical centers.
At Prevail
Tim serves as Managing Partner of Prevail Venture Capital Fund I. He leads MedTech and life-science sourcing for the firm, structures the rounds in which Prevail invests, and serves on the boards of portfolio companies where Prevail acts as lead investor.
He works closely with founders during diligence, generally accompanying them through the regulatory and commercial questions that determine whether a new therapeutic or device can reach a meaningful patient population at appropriate scale.
Where He Focuses His Attention
Tim’s sector attention tends toward investments with significant regulatory complexity. Devices and therapeutics where the pathway to market is well-defined but technically demanding. The opportunities that draw his interest are often the ones other firms decline because the regulatory work is the work.
The investments that age well in MedTech tend to be the ones where the regulatory path looks daunting from the outside. That barrier is also the moat.
Get in Touch
Tim works with founders building in MedTech, longevity, and adjacent life-science categories. Founders interested in Prevail’s MedTech practice can reach the team through the contact page or by emailing venture-capital@prevailiws.com.
Connect with Us
